IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025

Aggregated presentation by day and by market



Statement of transactions in own shares from August 18th to August 22nd 2025

Name of the issuer Identity code of the issuer

(Legal Entity Identifier) 		Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 18/08/2025 FR0010259150 600 113 CCXE
IPSEN 549300M6SGDPB4Z94P11 18/08/2025 FR0010259150 300 112,9 TQEX
IPSEN 549300M6SGDPB4Z94P11 18/08/2025 FR0010259150 3 261 113,41791 XPAR
IPSEN 549300M6SGDPB4Z94P11 19/08/2025 FR0010259150 300 114,5 AQEU
IPSEN 549300M6SGDPB4Z94P11 19/08/2025 FR0010259150 1 200 114,6 CCXE
IPSEN 549300M6SGDPB4Z94P11 19/08/2025 FR0010259150 300 114,6 TQEX
IPSEN 549300M6SGDPB4Z94P11 19/08/2025 FR0010259150 3 292 114,177 XPAR
IPSEN 549300M6SGDPB4Z94P11 20/08/2025 FR0010259150 300 116,1 AQEU
IPSEN 549300M6SGDPB4Z94P11 20/08/2025 FR0010259150 600 115,05 CCXE
IPSEN 549300M6SGDPB4Z94P11 20/08/2025 FR0010259150 300 116,096 TQEX
IPSEN 549300M6SGDPB4Z94P11 20/08/2025 FR0010259150 3 600 115,56664 XPAR
IPSEN 549300M6SGDPB4Z94P11 21/08/2025 FR0010259150 600 115,46 AQEU
IPSEN 549300M6SGDPB4Z94P11 21/08/2025 FR0010259150 300 115,9 CCXE
IPSEN 549300M6SGDPB4Z94P11 21/08/2025 FR0010259150 600 115,5 TQEX
IPSEN 549300M6SGDPB4Z94P11 21/08/2025 FR0010259150 3 189 115,33801 XPAR
IPSEN 549300M6SGDPB4Z94P11 22/08/2025 FR0010259150 300 117,156 AQEU
IPSEN 549300M6SGDPB4Z94P11 22/08/2025 FR0010259150 1 300 116,92308 CCXE
IPSEN 549300M6SGDPB4Z94P11 22/08/2025 FR0010259150 300 116,8 TQEX
IPSEN 549300M6SGDPB4Z94P11 22/08/2025 FR0010259150 3 340 117,19009 XPAR
      TOTAL 23 982 115,2171  

Attachment



EN
29/08/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

11h / 59m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

11h / 59m 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch